Search

Your search keyword '"Vertosick, Emily A."' showing total 525 results
Start Over Author "Vertosick, Emily A."
525 results on '"Vertosick, Emily A."'

1. Oncologic Outcomes of Incidental Versus Biopsy-diagnosed Grade Group 1 Prostate Cancer: A Multi-institutional Study

Author

Leni, Riccardo, Vertosick, Emily A., van den Bergh, Roderick C.N., Soeterik, Timo F.W., Heetman, Joris G., van Melick, Harm H.E., Roscigno, Marco, La Croce, Giovanni, Da Pozzo, Luigi F., Olivier, Jonathan, Zattoni, Fabio, Facco, Matteo, Dal Moro, Fabrizio, Chiu, Peter K.F., Wu, Xiaobo, Heidegger, Isabel, Giannini, Giulia, Bianchi, Lorenzo, Lampariello, Luca, Quarta, Leonardo, Salonia, Andrea, Montorsi, Francesco, Briganti, Alberto, Capitanio, Umberto, Carlsson, Sigrid V., Vickers, Andrew J., and Gandaglia, Giorgio

Published
2024
Full Text
View/download PDF

4. Individual Patient Data Meta-analysis of Discrimination of the Four Kallikrein Panel Associated With the Inclusion of Prostate Volume.

Author

Vertosick, Emily A, Zappala, Stephen, Punnen, Sanoj, Hugosson, Jonas, Boorjian, Stephen A, Haese, Alexander, Carroll, Peter, Cooperberg, Matthew, Bjartell, Anders, Lilja, Hans, and Vickers, Andrew J

Subjects
Prostate, Humans, Prostatic Neoplasms, Kallikreins, Prostate-Specific Antigen, Organ Size, Area Under Curve, ROC Curve, Aged, Middle Aged, Male, Neoplasm Grading, Aging, Urologic Diseases, Clinical Research, Cancer, Prostate Cancer, Clinical Sciences, Urology & Nephrology
Abstract

ObjectiveTo assess whether adding prostate volume to the kallikrein panel improves discrimination for ISUP Grade Group 2 or higher (GG2+) disease, as some men may have volume measurements available at the time of blood draw. While prostate volume predicts biopsy outcome, it requires an imaging procedure for measurement. The four kallikrein panel - commercially available as the 4Kscore - predicts risk of GG2+ disease and requires only a blood draw.Materials and methodsA total of 9131 patients with available prostate volume and total PSA ≤25 ng/ml from 5 historical (sextant biopsy, pre-ISUP 2005 grading) and 4 contemporary cohorts (10+ cores, ISUP 2005 grading). Previously published kallikrein panel models were used to predict risk of GG2+. Volume was added to the model in each cohort and change in discrimination was meta-analyzed.ResultsIncreased prostate volume was associated with decreased risk of GG2+ disease after controlling for the kallikrein panel in 7/9 cohorts. However, kallikrein panel discrimination (0.817, 95% CI 0.802, 0.831) was not improved after including volume (AUC difference 0.002, 95% CI -0.003, 0.006). Heterogeneity (P

Published
2021

5. Prospective validation of microseminoprotein‐β added to the 4Kscore in predicting high‐grade prostate cancer in an international multicentre cohort

Author

Lonergan, Peter E, Vertosick, Emily A, Assel, Melissa, Sjoberg, Daniel D, Haese, Alexander, Graefen, Markus, Boorjian, Stephen A, Klee, George G, Cooperberg, Matthew R, Pettersson, Kim, Routila, Erica, Vickers, Andrew J, and Lilja, Hans

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Cancer, Urologic Diseases, Prostate Cancer, Aged, Biomarkers, Tumor, Cohort Studies, Humans, Internationality, Kallikreins, Male, Middle Aged, Models, Statistical, Neoplasm Grading, Prospective Studies, Prostatic Neoplasms, Prostatic Secretory Proteins, Prostate&#8208, specific antigen, microseminoprotein&#8208, &#946, kallikreins, 4Kscore, prostate biopsy, #ProstateCancer, #PCSM, #uroonc, Prostate-specific antigen, microseminoprotein-β, Urology & Nephrology, Clinical sciences, Oncology and carcinogenesis
Abstract

ObjectivesTo prospectively evaluate the performance of a pre-specified statistical model based on four kallikrein markers in blood (total prostate-specific antigen [PSA], free PSA, intact PSA, and human kallikrein-related peptidase 2), commercially available as the 4Kscore, in predicting Gleason Grade Group (GG) ≥2 prostate cancer at biopsy in an international multicentre study at three academic medical centres, and whether microseminoprotein-β (MSP) adds predictive value.Patients and methodsA total of 984 men were prospectively enrolled at three academic centres. The primary outcome was GG ≥2 on prostate biopsy. Three pre-specified statistical models were used: a base model including PSA, age, digital rectal examination and prior negative biopsy; a model that added free PSA to the base model; and the 4Kscore.ResultsA total of 947 men were included in the final analysis and 273 (29%) had GG ≥2 on prostate biopsy. The base model area under the receiver operating characteristic curve of 0.775 increased to 0.802 with the addition of free PSA, and to 0.824 for the 4Kscore. Adding MSP to the 4Kscore model yielded an increase (0.014-0.019) in discrimination. In decision-curve analysis of clinical utility, the 4Kscore showed a benefit starting at a 7.5% threshold.ConclusionA prospective multicentre evaluation of a pre-specified model based on four kallikrein markers (4Kscore) with the addition of MSP improves the predictive discrimination for GG ≥2 prostate cancer on biopsy and could be used to inform biopsy decision-making.

Published
2021

12. A Contemporary Prostate Biopsy Risk Calculator Based on Multiple Heterogeneous Cohorts

Author

Ankerst, Donna P, Straubinger, Johanna, Selig, Katharina, Guerrios, Lourdes, De Hoedt, Amanda, Hernandez, Javier, Liss, Michael A, Leach, Robin J, Freedland, Stephen J, Kattan, Michael W, Nam, Robert, Haese, Alexander, Montorsi, Francesco, Boorjian, Stephen A, Cooperberg, Matthew R, Poyet, Cedric, Vertosick, Emily, and Vickers, Andrew J

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Aging, Prevention, Clinical Research, Prostate Cancer, Urologic Diseases, Cancer, Aged, Biopsy, Clinical Decision-Making, Decision Support Techniques, Digital Rectal Examination, Europe, Humans, Kallikreins, Male, Middle Aged, Neoplasm Grading, North America, Patient Selection, Predictive Value of Tests, Prospective Studies, Prostate-Specific Antigen, Prostatic Neoplasms, Reproducibility of Results, Risk Assessment, Risk Factors, Digital rectal exam, Family history, High-grade disease, Prostate cancer, Prostate-specific antigen, Risk prediction, Urology & Nephrology, Clinical sciences
Abstract

BackgroundProstate cancer prediction tools provide quantitative guidance for doctor-patient decision-making regarding biopsy. The widely used online Prostate Cancer Prevention Trial Risk Calculator (PCPTRC) utilized data from the 1990s based on six-core biopsies and outdated grading systems.ObjectiveWe prospectively gathered data from men undergoing prostate biopsy in multiple diverse North American and European institutions participating in the Prostate Biopsy Collaborative Group (PBCG) in order to build a state-of-the-art risk prediction tool.Design, setting, and participantsWe obtained data from 15 611 men undergoing 16 369 prostate biopsies during 2006-2017 at eight North American institutions for model-building and three European institutions for validation.Outcome measurements and statistical analysisWe used multinomial logistic regression to estimate the risks of high-grade prostate cancer (Gleason score ≥7) on biopsy based on clinical characteristics, including age, prostate-specific antigen, digital rectal exam, African ancestry, first-degree family history, and prior negative biopsy. We compared the PBCG model to the PCPTRC using internal cross-validation and external validation on the European cohorts.Results and limitationsCross-validation on the North American cohorts (5992 biopsies) yielded the PBCG model area under the receiver operating characteristic curve (AUC) as 75.5% (95% confidence interval: 74.2-76.8), a small improvement over the AUC of 72.3% (70.9-73.7) for the PCPTRC (p

Published
2018

15. TRANSVERSE VERSUS VERTICAL EXTRACTION SITE INCISION AFTER MINIMALLY INVASIVE RADICAL PROSTATECTOMY: A CLINICALLY INTEGRATED, CROSSOVER CLUSTER RANDOMIZED TRIAL

Author

Gaffney, Christopher D, primary, Vertosick, Emily A., additional, Laudone, Vincent, additional, Goh, Alvin C., additional, Carlsson, Sigrid V., additional, Pietzak, Eugene, additional, Donahue, Timothy, additional, Smith, Robert, additional, Touijer, Karim, additional, Vickers, Andrew J., additional, and Ehdaie, Behfar, additional

Published
2024
Full Text
View/download PDF

17. Interpreting Patient Reported Urinary and Sexual Function Outcomes across Multiple Validated Instruments

Author

Vertosick, Emily A, Vickers, Andrew J, Cowan, Janet E, Broering, Jeanette M, Carroll, Peter R, and Cooperberg, Matthew R

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Prostate Cancer, Clinical Research, Urologic Diseases, Cancer, Aged, Aged, 80 and over, Cohort Studies, Erectile Dysfunction, Humans, Male, Patient Outcome Assessment, Prostatic Neoplasms, Psychometrics, Sexual Dysfunction, Physiological, Surveys and Questionnaires, Urinary Incontinence, prostatic neoplasms, surveys and questionnaires, patient outcome assessment, urinary incontinence, erectile dysfunction, Urology & Nephrology, Clinical sciences
Abstract

PurposeComparing patient reported outcomes such as urinary and erectile function across institutions is critical for prostate cancer research and quality assurance. Such comparisons are complicated due to the use of different questionnaires. We aimed to develop a method to convert scores among 4 commonly used instruments.Materials and methodsPatient reported data on urinary and sexual function were collected on 1,284 men with localized prostate cancer using the EPIC-26 (Expanded Prostate Index Composite), PCI (UCLA Prostate Cancer Index), SHIM (Sexual Health Inventory for Men) and I-PSS (International Prostate Symptom Scale) questionnaires. We investigated several methods to convert scores among questionnaires.ResultsConversion between EPIC and PCI urinary and sexual function subscales was best achieved using only the subset of questions asked on both questionnaires. For the conversion between EPIC or PCI erectile function scores and SHIM scores, we defined thresholds of poor, intermediate and good function as EPIC/PCI 0 to 40 and SHIM 1 to 7, EPIC/PCI 41 to 59 and SHIM 8 to 16, and EPIC/PCI 60 to 100 and SHIM 17 to 25, respectively. Urinary continence scores highly correlated for PCI and EPIC (r = 0.94). No comparison was possible for I-PSS with EPIC and PCI due to differences in the domains addressed by these questionnaires.ConclusionsWe have introduced methods to convert scores among the EPIC, PCI and SHIM questionnaires. While these conversion methods may introduce minor imprecision, to our knowledge they represent the best available tools to combine and compare patient reported outcomes that are assessed using different instruments in men undergoing radical prostatectomy or active surveillance.

Published
2017

18. Oncologic Outcomes of Incidental Versus Biopsy-diagnosed Grade Group 1 Prostate Cancer: A Multi-institutional Study

Author

Arts-assistenten Radiotherapie, Leni, Riccardo, Vertosick, Emily A., van den Bergh, Roderick C.N., Soeterik, Timo F.W., Heetman, Joris G., van Melick, Harm H.E., Roscigno, Marco, La Croce, Giovanni, Da Pozzo, Luigi F., Olivier, Jonathan, Zattoni, Fabio, Facco, Matteo, Dal Moro, Fabrizio, Chiu, Peter K.F., Wu, Xiaobo, Heidegger, Isabel, Giannini, Giulia, Bianchi, Lorenzo, Lampariello, Luca, Quarta, Leonardo, Salonia, Andrea, Montorsi, Francesco, Briganti, Alberto, Capitanio, Umberto, Carlsson, Sigrid V., Vickers, Andrew J., Gandaglia, Giorgio, EAU-YAU Prostate Cancer Working Group, Arts-assistenten Radiotherapie, Leni, Riccardo, Vertosick, Emily A., van den Bergh, Roderick C.N., Soeterik, Timo F.W., Heetman, Joris G., van Melick, Harm H.E., Roscigno, Marco, La Croce, Giovanni, Da Pozzo, Luigi F., Olivier, Jonathan, Zattoni, Fabio, Facco, Matteo, Dal Moro, Fabrizio, Chiu, Peter K.F., Wu, Xiaobo, Heidegger, Isabel, Giannini, Giulia, Bianchi, Lorenzo, Lampariello, Luca, Quarta, Leonardo, Salonia, Andrea, Montorsi, Francesco, Briganti, Alberto, Capitanio, Umberto, Carlsson, Sigrid V., Vickers, Andrew J., Gandaglia, Giorgio, and EAU-YAU Prostate Cancer Working Group

Published
2024

19. Oncologic Outcomes of Incidental Versus Biopsy-diagnosed Grade Group 1 Prostate Cancer:A Multi-institutional Study

Author

Leni, Riccardo, Vertosick, Emily A., van den Bergh, Roderick C.N., Soeterik, Timo F.W., Heetman, Joris G., van Melick, Harm H.E., Roscigno, Marco, La Croce, Giovanni, Da Pozzo, Luigi F., Olivier, Jonathan, Zattoni, Fabio, Facco, Matteo, Dal Moro, Fabrizio, Chiu, Peter K.F., Wu, Xiaobo, Heidegger, Isabel, Giannini, Giulia, Bianchi, Lorenzo, Lampariello, Luca, Quarta, Leonardo, Salonia, Andrea, Montorsi, Francesco, Briganti, Alberto, Capitanio, Umberto, Carlsson, Sigrid V., Vickers, Andrew J., Gandaglia, Giorgio, Leni, Riccardo, Vertosick, Emily A., van den Bergh, Roderick C.N., Soeterik, Timo F.W., Heetman, Joris G., van Melick, Harm H.E., Roscigno, Marco, La Croce, Giovanni, Da Pozzo, Luigi F., Olivier, Jonathan, Zattoni, Fabio, Facco, Matteo, Dal Moro, Fabrizio, Chiu, Peter K.F., Wu, Xiaobo, Heidegger, Isabel, Giannini, Giulia, Bianchi, Lorenzo, Lampariello, Luca, Quarta, Leonardo, Salonia, Andrea, Montorsi, Francesco, Briganti, Alberto, Capitanio, Umberto, Carlsson, Sigrid V., Vickers, Andrew J., and Gandaglia, Giorgio

Abstract

Background and objective: Patients diagnosed with grade group (GG) 1 prostate cancer (PCa) following treatment for benign disease (“incidental” PCa) are typically managed with active surveillance (AS). It is not known how their outcomes compare with those observed in patients diagnosed with GG1 on biopsy. We aimed at determining whether long-term oncologic outcomes of AS for patients with GG1 PCa differ according to the type of diagnosis: incidental versus biopsy detected. Methods: A retrospective, multi-institutional analysis of PCa patients with GG1 on AS at eight institutions was conducted. Competing risk analyses estimated the incidence of metastases, PCa mortality, and conversion to treatment. As a secondary analysis, we estimated the risk of GG ≥2 on the first follow-up biopsy according to the type of initial diagnosis. Key findings and limitations: A total of 213 versus 1900 patients with incidental versus biopsy-diagnosed GG1 were identified. Patients with incidental cancers were followed with repeated biopsies and multiparametric magnetic resonance imaging less frequently than those diagnosed on biopsy. The 10-yr incidence of treatment was 22% for incidental cancers versus 53% for biopsy (subdistribution hazard ratio [sHR] 0.34, 95% confidence interval [CI] 0.26–0.46, p < 0.001). Distant metastases developed in one patient with incidental cancer versus 17 diagnosed on biopsy and were diagnosed with molecular imaging in 13 (72%) patients. The 10-yr incidence of metastases was 0.8% for patients with incidental PCa and 2% for those diagnosed on biopsy (sHR 0.35, 95% CI 0.05–2.54, p = 0.3). The risk of GG ≥2 on the first follow-up biopsy was low if the initial diagnosis was incidental (7% vs 22%, p < 0.001). Conclusions and clinical implications: Patients with GG1 incidental PCa should be evaluated further to exclude aggressive disease, preferably with a biopsy. If no cancer i

Published
2024

25. Do Phosphodiesterase Type 5 Inhibitors Increase the Risk of Biochemical Recurrence After Radical Prostatectomy?

Author

Flores, Jose M., primary, Vertosick, Emily, additional, Jenkins, Lawrence C., additional, Cooper, John, additional, Benfante, Nicole, additional, Sjoberg, Daniel, additional, Vickers, Andrew J., additional, Eastham, James A., additional, Laudone, Vincent P., additional, Scardino, Peter T., additional, Nelson, Christian J., additional, and Mulhall, John P., additional

Published
2024
Full Text
View/download PDF

48. Optimal Dissemination of Scientific Manuscripts via Social Media: A Prospective Trial Comparing Visual Abstracts Versus Key Figures in Consecutive Original Manuscripts Published in European Urology

Author

Klaassen, Zachary, primary, Vertosick, Emily, additional, Vickers, Andrew J., additional, Assel, Melissa J., additional, Novara, Giacomo, additional, Pierce, Cathy, additional, Wallis, Christopher J.D., additional, Larcher, Alessandro, additional, Cooperberg, Matthew R., additional, Catto, James W.F., additional, and Kutikov, Alexander, additional

Published
2022
Full Text
View/download PDF

49. sj-pdf-1-ctj-10.1177_17407745231185058 – Supplemental material for A randomized comparison of two-stage versus traditional one-stage consent for a low-stakes randomized trial

Author

Vickers, Andrew J, Vertosick, Emily A, Austria, Mia, Gaffney, Christopher D, Carlsson, Sigrid V, Kim, Scott YH, and Ehdaie, Behfar

Subjects
Pharmacology and Pharmaceutical Sciences not elsewhere classified, Sociological Methodology and Research Methods
Abstract

Supplemental material, sj-pdf-1-ctj-10.1177_17407745231185058 for A randomized comparison of two-stage versus traditional one-stage consent for a low-stakes randomized trial by Andrew J Vickers, Emily A Vertosick, Mia Austria, Christopher D Gaffney, Sigrid V Carlsson, Scott YH Kim and Behfar Ehdaie in Clinical Trials

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results